Syndax (NASDAQ: SNDX) posts preliminary 2025 Revuforj, Niktimvo sales and cash

Rhea-AI Filing Summary

Syndax Pharmaceuticals reported preliminary unaudited 2025 figures alongside a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company estimates U.S. net product revenue for Revuforj® (revumenib) at approximately $44 million for the fourth quarter and $125 million for the full year ended December 31, 2025. Niktimvo™ (axatilimab-csfr) generated an estimated $56 million in U.S. net product revenue for the quarter and $152 million for the full year, with Syndax to report its share of net commercial profit when it releases full-year 2025 results. The company also disclosed preliminary total cash, cash equivalents and marketable securities of about $394 million as of December 31, 2025. All figures are unaudited and subject to change as the year-end audit is completed.

Insights

Biopharma earnings and liquidity analyst

Preliminary 2025 product revenues and cash position look sizable but are unaudited and lack comparison data.

The company reports preliminary U.S. net product revenue for Revuforj® (revumenib) of approximately $44 million in Q4 and $125 million for full-year 2025. For Niktimvo™ (axatilimab-csfr), preliminary U.S. net product revenue is about $56 million in Q4 and $152 million for the same year. These figures indicate two commercial products already contributing meaningful sales, but the excerpt does not include prior-year data to gauge growth.

The disclosure also notes preliminary total cash, cash equivalents and marketable securities of around $394 million as of December 31, 2025, which provides a snapshot of liquidity at year end. All numbers are expressly described as unaudited, preliminary and subject to potential adjustment as the audit for the year ended December 31, 2025 is completed. The company states it will report its share of Niktimvo net commercial profit when it releases full-year 2025 results, so a clearer view of profitability will depend on those future, fully audited disclosures.

0001395937false00013959372026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

SYNDAX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37708	32-0162505
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
730 THIRD AVENUE FLOOR 9
NEW YORK, New York				10017
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 419-1400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		SNDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release in connection with the Company’s presentation on the same date at the 44th Annual J.P. Morgan Healthcare Conference that contains certain preliminary financial information as of and for the fiscal year ended December 31, 2025. Specifically, the press release states that (i) the Company achieved approximately $44 million and $125 million in preliminary (unaudited) U.S. net product revenue for Revuforj® (revumenib) for fiscal quarter and year ended December 31, 2025, respectively, (ii) Niktimvo™ (axatilimab-csfr) achieved $56 million and $152 million in preliminary (unaudited) U.S. net product revenue for fiscal quarter and year ended December 31, 2025, respectively, and the Company will report it’s share of net commercial profit when it reports full year 2025 results, and (iii) the Company’s total preliminary cash, cash equivalents and marketable securities (unaudited) was approximately $394 million as of December 31, 2025.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company’s results of operations for the fiscal year ended December 31, 2025, or financial condition as of December 31, 2025. The preliminary selected financial results reported by the Company for the fourth quarter and full-year 2025 are provided only as an approximation in advance of the Company’s announcement of complete financial results in early 2026. This information is based on currently available information. The audit of the Company’s financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01.

The information contained in Item 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated January 12, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SYNDAX PHARMACEUTICALS, INC.
Date:	January 12, 2026	By:	/s/ Michael A. Metzger
			Michael A. Metzger Chief Executive Officer

FAQ

What preliminary 2025 revenue did Syndax Pharmaceuticals (SNDX) report for Revuforj?

The company reported preliminary unaudited U.S. net product revenue for Revuforj® (revumenib) of approximately $44 million for the fourth quarter and $125 million for the full year ended December 31, 2025.

How much preliminary 2025 revenue did Niktimvo generate for Syndax Pharmaceuticals (SNDX)?

Niktimvo™ (axatilimab-csfr) achieved preliminary unaudited U.S. net product revenue of about $56 million for the fourth quarter and $152 million for the full year ended December 31, 2025.

What is Syndax Pharmaceuticals’ preliminary cash and investments balance at year-end 2025?

The company reported total preliminary unaudited cash, cash equivalents and marketable securities of approximately $394 million as of December 31, 2025.

Are Syndax Pharmaceuticals’ reported 2025 figures for Revuforj and Niktimvo audited?

No. The company states that all the disclosed 2025 figures are preliminary and unaudited, and that the ongoing audit for the year ended December 31, 2025 could result in changes.

When will Syndax Pharmaceuticals (SNDX) report its share of Niktimvo net commercial profit?

The company indicates it will report its share of net commercial profit from Niktimvo™ when it releases its full-year 2025 financial results.

What event prompted Syndax Pharmaceuticals to disclose these preliminary 2025 results?

The preliminary figures were shared in connection with the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.